A Hydroxyzine Hydrochloride Tablet is a solid oral pharmaceutical dosage form with Hydroxyzine Hydrochloride as the active pharmaceutical ingredient (API) at a strength of 10mg per dosage unit. Hydroxyzine Hydrochloride 10mg Tablets are created by regulated tablet production protocols for content uniformity, tablet weight, physical property, and reproducibility of quality. Expanding the solid oral part of your pharmaceutical franchise, Hydroxyzine Hydrochloride 10mg Tablets can be added to your portfolio as a PCD Pharma Franchise solution.
A Hydroxyzine Hydrochloride Tablet includes the API with suitable excipients according to a finalized formulation. Manufacturing of a tablet involves measured dispensing, blending, compression using either direct compression or a granulation process where relevant, lubrication, coating optional, tablet testing, and packaging.
The API was initially qualified to meet the necessary raw-material specification criteria, then released for formulation development. Alternatively, the API can be qualified to meet market-specific sale specifications and/or the finished-product specifications used for high-volume marketed products.
Accuracy of dispensing is critical to preserve dosage strength within the tablet formulation and enable traceability. Equipment for weighing the API should be calibrated and validated for use before manufacturing.
Suitable pharmaceutical excipients are selected per the final formulation design. These may provide functionality related to flow, compression, binding, disintegration, lubrication, or appearance and physical stability of the finished product.
Compatibility screening between the API and various excipients can be assessed during formulation development. The final formulation is finalized through control studies to optimize performance and established through a validated manufacturing method.
The bulk hydroxyzine tablet API is dispensed accurately using validated procedures before entering a process of combination with added excipients. Depending on the formulation, mixing can be achieved through direct compression or a dry or wet granulation approach designed into the formulation as appropriate. Blending parameters are measured to assure homogeneity and immediate output stability.
Particle size distribution and flow properties can be optimized at the formulation stage. The API should be present at a low level within the final formulation and therefore, precise blending procedures should be implemented to minimize variations.
Granulation (either wet or dry) is performed according to the process design. Compression time, pressure, and punch configuration parameters are monitored to ensure tablet weight, appearance, and hardness remain consistent. In-process assessments may be performed at intervals throughout manufacturing.
Equipment cleaning, calibration, and maintenance are conducted before production to confirm valid results. Records are maintained for each batch of components, equipment identification, in-process assessments, yields, and other manufacturing details.
Hydroxyzine hydrochloride 10mg Tablet physical quality relies on controlled processing. Tableting specifications include standard weight, assessment of average weight and variation, tablet weight variation can be verified, in-process tablet weight checks, hardness testing, thickness measurement, friability testing, visual evaluation, and appearance.
Tablet coating is optional depending on final formulation requirements. Coating parameters can be measured where relevant, including spray rate, coating weight gain, product temperature, and conditions for drying. Controlled coating protocols result in desired product coating characteristics.
Controlled manufacturing requires calibration, quality-controlled maintenance of equipment, and batch-specific recording of component mass, operations and yields, in-process adjustments, and final weight, height, coating, and appearance.
Through the use of accelerated and long-term storage tests, the stability of the new formulation can be established. Elements examined include physical appearance, coating weight gain if applied, dissolution, assay, related substance testing, and other quality characteristics.
Finished product testing can include identification, assay, related substances, disintegration, dissolution, and weight variation. The finished product can be tested for uniformity where applicable.
Testing of process control testing points can assist with system validation and consistency between batches. Testing of the API to meet pre-set raw-material specifications can establish that the API used meets the specifications and quality parameters required for a stable, high-quality product.
Calibration of laboratory instruments and preparation of control standards can assist in consistent assessment of finished products. Repeat analysis by a second analyst can verify results and help ensure validity.
The packaging materials and presentation influence the ability of the final product to be protected from physical damage and environmental exposure during transit, handling, and storage. The packaging selection is chosen to meet the specification for the product and provide the required protection, ease of handling, and visual identification.
Suitable blisters, strips, or alternative packaging forms that best address these specifications can be selected. Tapes, seals, and closures should be chosen to provide an effective barrier and protector for the finished product.
Secondary packaging provides information about the product content and its specific identification, the batch lot number, the expiry date, storage conditions, and quality controls. The finished product is introduced into a PCD Pharma Franchise portfolio with a processing framework that validates input quality, quantity, and content identification through documented procedures, calibrated equipment, and controlled operations for blended powders or granules, compression, coating, and packaging.
Order analysis, records for in-process checks, labels, labels, lot control, and validated systems of production help guarantee that acceptable quality is maintained through the production run and as part of a formulation in your portfolio. These actions ensure that hydroxyzine hydrochloride 10 mg tablets within your product portfolio and distribution systems are comparable from batch to batch and exceed specified criteria as part of your PCD Pharma Franchise initiative.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech